All News

A review updates MASH diagnosis and prognosis guidelines, highlighting noninvasive scores, imaging, and emerging therapies, plus lifestyle strategies to improve outcomes.

PBM reforms, Medicare Advantage trends, TrumpRx launch, and Express Scripts settlement highlight key shifts in drug pricing, coverage, and patient access.

A survey found many patients with long-term conditions prefer remote visits for results and refills, but some trade continuity for faster care.

Vishal A. Patel, MD, explains that delayed skin cancer diagnoses contribute to more advanced disease and poorer outcomes in patients with darker skin.

MicroRNAs are central regulators of DLBCL biology and show strong potential as minimally invasive biomarkers to improve disease classification, prognosis, and treatment personalization.

The Consolidated Appropriations Act of 2026 acts as a first step in addressing prescription drug pricing challenges related to the role of pharmacy benefit managers (PBMs).

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

A Quebec cohort study links gas station proximity to higher VOC exposure and elevated childhood cancer risk, especially acute lymphoblastic leukemia.

The postpandemic reinstatement of Medicare’s 3-day rule lengthened hospital stays without affecting SNF use, spending, or short-term outcomes, raising questions about its value.

To protect patients, the FDA will restrict ingredients in unapproved compounded GLP‑1 drugs and crack down on misleading marketing.

From prior authorization delays to PBM reforms and Medicaid gaps, experts track policy shifts that shape health equity and health care access nationwide.

Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by underlying stroke etiology.

The authors call for policy reforms that could strengthen patient-provider relationships, support care innovation, and improve quality for Medicare beneficiaries.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

Alopecia profoundly disrupts identity, emotional wellbeing, and social life, with many people struggling due to stigma, concealment pressures, and unmet psychological support needs.

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Study links elevated serum haptoglobin to chronic spontaneous urticaria activity, suggesting it predicts treatment response and complete disease control.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

ED dizziness visits see rising MRI use at discharge; exam-guided imaging helps detect missed strokes and informs secondary prevention.

Stroke recovery improves when care addresses social needs like reducing loneliness and depression and strengthening support.

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions.